MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Gleevec safe and effective over the long term

Back to research news Blogs list Cancer blog  


Subscribe To Research News RSS Feed  RSS content feed What is RSS feed?

Gleevec safe and effective over the long term




The drug imatinib mesylate, more usually known as Gleevec®, proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), as per a research studyprepublished online in Blood, the official journal of the American Society of Hematology.

A team of scientists from the U.S. and Europe, including the drug's creator, Brian Druker, MD, followed 454 patients with chronic-phase CML taking imatinib for more than six years. Previous to enrollment, all study participants had experienced either therapy failure or intolerance with interferon alpha, which was the standard of care for CML at the time the study was initiated.



Gleevec safe and effective over the long term

"The long-term follow-up results of imatinib in CML post interferon failure reassure us of the high efficacy of the drug and its safety," stated Hagop Kantarjian, MD, the lead author on the study and Chairman and Professor of the Leukemia Department at the University of Texas M.D. Anderson Cancer Center. "With a six-year follow-up, the estimated six-year survival rate is 76 percent. In historical data, after interferon failure the average survival was about three to four years".

Imatinib dosage began at 400 milligrams per day and was escalated to 600 mg/d or 800 mg/d in patients who did not achieve positive therapy responses within set time periods or whose disease relapsed.

The best possible therapy outcome - a complete cytogenetic response, which is the elimination of the genetic abnormality linked to the disease - occurred in 57 percent of the study participants and was achieved in a median time of eight months. Overall survival rates and avoidance of disease progression were strongly correlated with cytogenetic response by 12 months; those with a minimal or no cytogenetic response within the first year faired poorly.

The occurence rate of serious side effects was low and, eventhough 15 cases of heart dysfunction were reported in study participants, only four cases were considered to be drug-related. During the study, 35 patients discontinued the drug because of adverse events or abnormal test results.

"About half of the patients on the study continue to receive imatinib and 40 percent are in complete cytogenetic response," said Dr. Kantarjian. "No long-term new toxicities have been observed. In particular, the drug-related cardiac toxicity, which was reported to be of concern last year, was quite rare".

This clinical trial was the basis for the first approval of imatinib for CML, which has since become the standard of care for the disease.


Posted by: Scott    Source




Did you know?
The drug imatinib mesylate, more usually known as Gleevecandreg;, proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), as per a research studyprepublished online in Blood, the official journal of the American Society of Hematology.

Medicineworld.org: Gleevec safe and effective over the long term

Acute bacterial meningitis| Alzheimer's disease| Carpal tunnel syndrome| Cerebral aneurysms| Cerebral palsy| Chronic fatigue syndrome| Cluster headache| Dementia| Epilepsy seizure disorders| Febrile seizures| Guillain barre syndrome| Head injury| Hydrocephalus| Neurology| Insomnia| Low backache| Mental retardation| Migraine headaches| Multiple sclerosis| Myasthenia gravis| Neurological manifestations of aids| Parkinsonism parkinson's disease| Personality disorders| Sleep disorders insomnia| Syncope| Trigeminal neuralgia| Vertigo|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.